IsoRay, Inc. (ISR)
-NYSE MKT 0.51 
0.00(0.20%) May 17, 4:00PM EDT
| Prev Close: | 0.51 |
|---|
| Open: | 0.50 |
|---|
| Bid: | 0.48 x 10000 |
|---|
| Ask: | 0.80 x 5000 |
|---|
| 1y Target Est: | N/A |
|---|
| Beta: | -1.56 |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | 0.49 - 0.51 |
|---|
| 52wk Range: | 0.35 - 1.60 |
|---|
| Volume: | 21,145 |
|---|
| Avg Vol (3m): | 134,565 |
|---|
| Market Cap: | 17.64M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -0.12 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- IsoRay, Inc. Reports Third Quarter ResultsMarketwired(Wed, May 15)
- ISORAY, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and ExhibitsEDGAR Online(Wed, May 15)
- ISORAY, INC. Files SEC form 10-Q, Quarterly ReportEDGAR Online(Tue, May 14)
- A Look At The Prostrate Cancer Treatment Marketat Seeking Alpha(Wed, Apr 17)
- IsoRay on Display at the American Brachytherapy Society (ABS) Convention Featuring Its Cesium-131 Cancer Fighting PortfolioMarketwired(Mon, Apr 15)
- ISORAY, INC. Files SEC form 8-K/A, Entry into a Material Definitive AgreementEDGAR Online(Thu, Mar 21)
- ISORAY, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security HoldersEDGAR Online(Wed, Feb 27)
- IsoRay says policy is not to comment on unusual market activitytheflyonthewall.com(Wed, Feb 27)
- IsoRay, Inc. States Its Policy Not to Comment on Unusual Market ActivityPR Newswire(Wed, Feb 27)
- ISORAY, INC. FinancialsEDGAR Online Financials(Thu, Feb 21)
- First International Brain Cancer Treatments Performed Utilizing IsoRay's GliaSite Radiation Therapy SystemMarketwired(Thu, Feb 21)
- ISORAY, INC. Files SEC form 10-Q, Quarterly ReportEDGAR Online(Thu, Feb 14)
- ISORAY, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and ExhibitsEDGAR Online(Thu, Feb 14)
- IsoRay, Inc. Reports Second Quarter ResultsMarketwired(Thu, Feb 14)
- Cancer Radiation Stocks To Consider: Delcath, Spectrum And IsoRayat Seeking Alpha(Tue, Feb 5)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 3.78 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Jun-13)
: | -0.12 |
|---|
| Quarterly EPS Est
(Jun-13)
: | -0.03 |
|---|
| Mean Recommendation*: | 3.0 |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
IsoRay, Inc. engages in the development, manufacture, and sale of isotope-based medical products and devices for the treatment of cancer and other malignant diseases primarily in the United States.
View More